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Background: Although a drug-eluting stent (Zilver PTX) has become available for
endovascular therapy (EVT) for peripheral artery disease in Japan, outcomes
following EVT using Zilver PTX for patients presenting with femoropopliteal (FP)
artery lesions remain to be elucidated. This study focuses on midterm outcomes.
Methods: Between July 2012 and March 2013, FP lesions in 106 limbs from 89
patients were treated with Zilver PTX. Primary outcome including primary patency
and freedom from clinically driven target lesion revascularization (TLR) were
analyzed by Kaplan-Meier estimation. Restenosis (diameter stenosis >50%) was
assessed with angiography at 12 months. Furthermore, we compared patency of TASC
A/B with C/D by log-rank test.
Results: At 1-year, primary patency and TLR rate were 71% and 85%, respectively.
There were no signiﬁcant differences between patency of TASC A/B and C/D
(P ¼ 0.28).
Conclusion: Midterm outcome was acceptable after Zilver PTX stent implantation in
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Background: Sometimes we can’t achieve wound healing in patients with critical
limb ischemia (CLI) with tissue loss even after successful endovascular therapy
(EVT). Multiple factors including patient background, intervention outcomes, and also
wound characteristics are associated with wound healing. Therefore we evaluated
predictors of wound healing in CLI after successful EVT.S28 JACC Vol 63/12/Suppl S j April 22–25, 2014 j TCTAP AbstractsMethods: Between April 2007 and April 2012, 179 patients (217 limbs) with CLI
classiﬁed to Rutherford 5 or 6 were treated with EVT in our institute. Of these, 161
individual wounds (128 patients, 146 limbs) were successfully treated. Successful
EVT was deﬁned as revascularization of achievement of direct blood ﬂow to the
wounds evaluated by digital subtraction angiography just after EVT. Each variables
were analyzed using the univariate Cox proportional hazards model for wound
healing. All variables tested in univariate analysis with p < 0.25 were included in
multivariate Cox hazards model.
Results: The mean follow-up period was 2117 months. Wound healing rates were
41%, 58%, 71%, and 72%, at 3, 6, 12, and 18 months, respectively. Multivariate Cox
proportional hazard analysis revealed that insulin use (HR 0.494, 95%CI 0.318-0.766,
p¼0.002), dependence on hemodialysis (HR 0.40, 95%CI 0.257-0.623, p<0.001),
low ejection fraction (HR 0.438, 95%CI 0.205-0.935, p¼0.033), and not toe wounds
(HR 0.388, 95%CI 0.253-0.594, p<0.001) were independent adverse predictors of
wound healing following successful EVT.
Conclusion: Achievement of direct blood ﬂow to the wounds is important factor for
wound healing, but that is not enough. Insulin use, dependence on hemodialysis, low
ejection fraction, and not toe wounds were adverse independent predictors of wound
healing.
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Background: The ﬁrst drug eluting peripheral stent of Zilver PTX (COOK Medical)
showed higher primary patency rate over plain old balloon and/or bare Zilver stent in
TASC (A) and (B) lesions in superﬁcial femoral artery (SFA) disease from the Zilver
PTX Randomized Trial. This study led to the approval Zilver PTX in Japan. But, in
real world clinical practice, we have to deal with more complex SFA disease and
previously implanted SFA in-stent restenosis. We need to clarify restenosis rate, target
lesion revascularization rate (TLR) and restenosis pattern of Zilver PTX in real clinical
cases. The purpose of this study was to investigate restenosis rate, target lesion
revascularization rate (TLR) and angiographic patterns of in-stent restenosis (ISR)
after Zilver PTX stenting in real world SFA disease.
Methods: The study was prospective maintained database, retrospective analyzed by
two centers. Between July 2012 and March 2013, 65 consecutive patients (pts) with 65
lesions (mean age 72 years, 68% male) underwent successful Zilver PTX stenting for
SFA disease on either de novo or in-stent restenosis (ISR). The following parameters
were documented before the intervention, immediately afterward, 6, 9 and 12 months
later: clinical stage, ankle-brachial index, peak systolic velocity ratio (PSVR) and TLR.
Restenosis was deﬁned as >2.5 of PSVR. In TLR cases, restenotic pattern were clas-
siﬁed into three Classes. Class I is the focal (<50 mm in length) ISR group, included
lesions positioned at the stent body, the stent edge, or a combination of these sites. Class
II is the diffuse (>50 mm in length) ISR group, includes not only stent body lesions, but
also stent edge lesions and Class III is the totally occluded ISR group.
Results: 71% of the 65 pts were in claudicant and 29% in critical limb ischemia.
40% were on hemodialysis. Mean lesion length was 17491mm and the number of
stented Zilver PTX were 1.90.8. Mean follow up period was 8.73.1 months. 65%
of TASC (C) and (D), 32% of pre ISR patients were included. Primary patency rate
was 75%, 62%, 57% and freedom from TLR was 92%, 74%, 63% at 6, 9, 12
months, respectively. In 20 cases of TLR analysis, restenotic pattern were 15% (3
cases) in Class I, 25% (5 pts) were Class II, 60 %( 12 pts) were in Class III.
Multivariate analysis for ISR by prespeciﬁed risk factors, the lesion which was pre
ISR (HR 2.5, 95%CI 0.6–9.7, p¼0,032), over 2 stents use (HR 4.5, 95%CI 1.3–13.4,
p¼0.019), and the pts on Cilostazol (HR 5.4, 95%CI 1.0–35.0, p¼0.045) were an
independent negative predictor for restenosis. And pre ISR (HR 11.4, 95%CI 2.1–
87.7, p¼0.003), chronic total occlusion (HR 9.2, 95%CI 1.5–90.4 p¼0.014), over 3
stents use (HR 2.1 95%CI 1.3–13.9, p¼0.046) were signiﬁcant negative predictor of
class III.
Conclusion: The most commonly seen restenotic pattern of ﬁrst drug eluting stent,
Zilver PTX was class III (in-stent-re-occlusion). And its negative predictors of Zilver
PTX patency were pre ISR, chronic total occlusion and over 3 stents use. These
results were consistent with previously mentioned results of those bare metal Nitinol
stents.
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Background: The success rate of endovascular therapy (EVT) for long chronic total
occlusion (CTO) of femoropopliteal arteries has improved because of devices/ORAL/Peripheral Vascular Intervention (Non-carotid, Non-neurovascular)
